로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell Grade Beads > CD19 > MBS-C002

ActiveMax® Human CD19 μBeads, premium grade (for cells) DMF

The Magnetic Stand (Cat.No. MB-01 & Cat.No. MB-02) can be used in conjunction with Beads.

Order Now

ProductSizeAmount
ActiveMax® Human CD19 μBeads, premium grade (for cells)2.5 mg2.5 × 10⁷ beads
ActiveMax® Human CD19 μBeads, premium grade (for cells)10 mg (2.5 mg × 4)1.0 × 10⁸ beads
  • Product Description
    ActiveMax® Human CD19 μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human CD19 protein expressed from human 293 cells (HEK293) and contains AA Pro 20 - Lys 291 (Accession # P15391-1). ActiveMax® Human CD19 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.
  • Application
    ActiveMax® Human CD19 μBeads, premium grade (for cells) are designed to stimulate in vitro CD19-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human CD19 antigen. It can be used as follows:
    Evaluating the characteristics of CAR-T cells or UCAR-T cells.
    In vitro expansion of CD19-specific CAR-T cells or UCAR-T cells.
    In vitro enrichment of CD19-specific CAR-T cells or UCAR-T cells.
  • Reconstitution

    See Certificate of Analysis (CoA) for detailed instruction.

  • Storage
    This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.Please avoid repeated freeze-thaw cycles after reconstitution. Immediate use after reconstitution is highly recommended.
  • Sterility
    Negative
  • Endotoxin
    Less than 0.002 EU per μg by the LAL method / rFC method.
  • Important Note
    This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

Typical Data Please refer to DS document for the assay protocol.
 CD19 TYPICAL DATA

Assay of human CD19 protein on the μBeads surface by Flow cytomtry. The human CD19 conjugated on the μBeads (Cat. No. MBS-C002) surface were fluorescently stained using PE labeled anti-human CD19 antibody and analyzed by flow cytometry (QC tested).

 CD19 TYPICAL DATA

ActiveMax® Human CD19 μBeads, premium grade (for cells) (Cat. No. MBS-C002) can activate CD19-specific CAR-T cells by detecting the secretion of IFN- γ in vitro (Routinely tested).

 CD19 TYPICAL DATA

CD19 CAR-T cells were stimulated with ActiveMax® Human CD19 μBeads (MBS-C002) for 24 h , and cell-free supernatants were harvested for evaluating IFN-γ secretion by ELISA. The results showed that CD19 CAR-T cells released significantly larger amounts of IFN-γ into the supernatants in response to CD19 μBeads . Seed the CD19 μBeads in 96-well plates at a density of 2×10⁴ μBeads/well, and co-culture with CD19 CAR-T cells at an effector-to-target (E:T) ratio of 5:1, 1:1, 1:5 in 96-well tissue culture plate, respectively. CD19 CAR-T cells alone were cultured as the control.

 CD19 TYPICAL DATA

CD19 CAR-T cells were stimulated with ActiveMax® Human CD19 μBeads (MBS-C002) for 24 h , and cell-free supernatants were harvested for evaluating IFN-γ secretion by flow cytomtry. The results showed that CD19 CAR-T cells released significantly larger amounts of IFN-γ into the supernatants in response to CD19 μBeads. Seed the CD19 μBeads in 96-well plates at a density of 2×10⁴ μBeads/well, and co-culture with CD19 CAR-T cells at an effector-to-target (E:T) ratio of 5:1, 1:1, 1:5 in 96-well tissue culture plate, respectively. CD19 CAR-T cells alone were cultured as the control.

Application Data
 CD19 APPLICATION DATA

CD19 CAR-T cells were stimulated with ActiveMax® Human CD19 μBeads (MBS-C002) for 24h, and cells were harvested for evaluating CD69,CD137 expression by flow cytometry. The results showed that the proportion of CD69 and CD137 in CD19 CAR-T cells was significantly increased after CD19 μBeads stimulation.

Seed the CD19 μBeads in 96-well plates at a density of 2×10⁴ μBeads/well, and co-culture with CD19 CAR-T cells at an effector-to-target (E:T) ratio of 5:1, 1:1, 1:5 in 96-well tissue culture plate, respectively. CD19 CAR-T cells alone were cultured as the control.

 CD19 APPLICATION DATA

CD19 CAR-T cells were stimulated with ActiveMax® Human CD19 μBeads (MBS-C002) for 24h, and cell-free supernatants were harvested for evaluating Granzyme B, Perforin secretion by ELISA. The results showed that CD19 CAR-T cells released significantly larger amounts of Granzyme B, Perforin into the supernatants in response to CD19 μBeads.

Seed the CD19 μBeads in 96-well plates at a density of 2×10⁴ μBeads/well, and co-culture with CD19 CAR-T cells at an effector-to-target (E:T) ratio of 5:1, 1:1, 1:5 in 96-well tissue culture plate, respectively. CD19 CAR-T cells alone were cultured as the control.

 CD19 APPLICATION DATA

After positive selection with the ActiveMax Human CD19 ubeads at 2:4 (beads : cells), the proportion of CAR cells that enriched cells were ≈150-fold higher than that of the initial population - 0.1%.

 CD19 APPLICATION DATA

To simulate difficult enrichment conditions, used CAR cells with low CAR expression. CAR cells in initial stained populations were rare (~ 0.1%). CD19 CAR-T cells were stimulated with ActiveMax® Human CD19 μBeads (MBS-C002) for 24 h. Transfer the tube on a magnet to separate the beads-CAR-T cells from the solution. Carefully pipette off the supernatant to a new tube, this is the unlabeled cell fraction. Wash isolated beads-cells complex (enriched CAR-T cells). Remove the tube from the magnet, resuspend the isolated beads-cells complex and then analyzed with FACS.

  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(USD) : $1788.00

Price(USD) : $4389.00

Drug Development Status

  • Number of Launched Drugs:10 Details
  • Number of Drugs in Clinical Trials:279 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message